Article
Hematology
Andreea Sima, Peter Hollander, Eva Baecklund, Karin E. Smedby, Gunilla Enblad, Rose-Marie Amini
Summary: This study assessed the prevalence of viral hepatitis and AID in SMZL patients in a Swedish population and their treatment outcomes. The study found that upfront splenectomy was associated with better overall survival and progression-free survival. History of viral hepatitis and AID did not impact the outcomes of SMZL.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Review
Oncology
Roberto Castelli, Monica Balzarotti, Emanuele Salvi, Roberta Simona Rossi, Giorgio Lambertenghi Deliliers, Luigi Bergamaschini, Antonio Gidaro
Summary: Splenic marginal zone lymphoma (SMZL) is a rare lymphoproliferative disease affecting elderly patients. It primarily involves the peripheral blood, bone marrow, and spleen, while sparing the lymph nodes. The prolonged antigen stimulation of B lymphocytes and microenvironment play a crucial role in the development of SMZL. NOTCH2 and NFk-B signaling integration has been identified as the primary mechanism of neoplastic proliferation in SMZL. The prognosis of SMZL depends on individual risk factors and patients' health status.
Article
Oncology
Alexander Grunenberg, Lisa M. Kaiser, Stephanie Woelfle, Birgit Schmelzle, Andreas Viardot, Peter Moeller, Thomas F. E. Barth, Rainer Muche, Jens Dreyhaupt, Markus Raderer, Barbara Kiesewetter, Christian Buske
Summary: The COUP-1 trial aims to evaluate the efficacy and toxicity of copanlisib in combination with rituximab in patients with MZL, while also offering the opportunity for translational research in this heterogeneous type of lymphoma.
Article
Hematology
Olga Mulas, Giovanni Caocci, Daniela Dessi, Daniela Mantovani, Giulia Moi, Maria Giuseppina Cabras, Giorgio La Nasa
Summary: In a single-center cohort study of 68 patients with SMZL, it was found that treatment with rituximab monotherapy or in combination with bendamustine resulted in a higher 5-year progression-free survival compared to rituximab combined with polychemotherapy. Additionally, low platelet count at diagnosis and transformation into diffuse large B-cell lymphoma were associated with lower overall survival in SMZL patients.
ACTA HAEMATOLOGICA
(2021)
Review
Hematology
Yawen Wang, Jiadai Xu, Jing Li, Zheng Wei, Miaojie Shi, Rong Tao, Bobin Chen, Yuyang Tian, Wenhao Zhang, Yan Ma, Lihua Sun, Yunhua Hou, Qilin Zhan, Jigang Wang, Hongwei Xue, Peng Liu
Summary: This multicenter retrospective study evaluated the efficacy and safety of R-2CdA in patients with MZL. The study found that R-2CdA was as effective as R-CHOP in terms of overall response rate and complete response rate, while being more tolerable in MZL patients.
ANNALS OF HEMATOLOGY
(2022)
Article
Oncology
Taha Ulutan Kars, Zahit Furkan Yorganci, Osman Yaskiran, Atakan Tekinalp, Sinan Demircioglu
Summary: Rituximab is a widely used chimeric monoclonal antibody for treating B-cell lymphoma. It has various side effects, including allergic reactions and neurological effects. Long-term administration of rituximab may lead to thrombocytopenia. This case report highlights a rare occurrence of rituximab-induced acute thrombocytopenia in a patient with splenic marginal zone lymphoma. The patient experienced a severe drop in platelet count after rituximab administration, which was managed with thrombocyte suspension and close monitoring.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2023)
Article
Hematology
Gabriela Bastidas-Mora, Silvia Bea, Alba Navarro, Eva Gine, Dolors Costa, Julio Delgado, Tycho Baumann, Laura Magnano, Alfredo Rivas-Delgado, Neus Villamor, Dolors Colomer, Monica Lopez-Guerra, Maria Rozman, Olga Balague, Daniel Martinez, Maria Joao Baptista, Lourdes Escoda, Miguel Alcoceba, Margarita Blanes, Fina Climent, Elias Campo, Andrew Wotherspoon, Armando Lopez-Guillermo, Estella Matutes
Summary: The study describes 36 patients with splenic marginal zone lymphoma (SMZL) with transformation, with predictors including cytopenias, hypoalbuminaemia, and complex karyotype. Patients with SMZL-T have a higher risk of death, mostly developing diffuse large B-cell lymphoma post transformation, with predictors for worse survival being high-risk International Prognostic Index and lack of complete response.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Medicine, Research & Experimental
Kei Nakayama, Takeshi Yoshida, Yoshiaki Nakayama, Noriaki Iguchi, Yuta Namba, Morichika Konishi, Hiroshi Hasegawa
Summary: This study focused on investigating the impact of malnutrition on the spleen, revealing significant reductions in spleen weight and red pulp ratio in dietary-restricted mice. It was found that macrophages in the marginal zone of the spleen play a crucial role in the dietary restriction-induced splenic involution.
Article
Medicine, General & Internal
Kendra Naismith, Pat A. Allevato, Caroline Hamm
Summary: This case report describes a 38-year-old woman with a rare presentation of factor VII inhibitor associated with splenic marginal zone lymphoma. The patient was successfully treated with rituximab immunotherapy, confirmed by splenectomy, and has remained in remission for 12 years. This case supports the causative relationship between splenic marginal zone lymphoma and factor VII inhibitor.
AMERICAN JOURNAL OF CASE REPORTS
(2021)
Article
Hematology
Ana Muntanola, Maria Teresa Villalobos, Sonia Gonzalez-Villambrosia, Maria Jose Rodriguez-Salazar, Ana Jimenez-Ubieto, Gabriela Bastidas-Mora, Raul Cordoba, Maria Infante, Maria Jesus Vidal, Francisco Javier Diaz, Monica Baile, Mariana Bastos-Oreiro, Carlos Panizo, Juan Manuel Sancho, Belen Navarro, Tomas Garcia, Lourdes Escoda, Pau Abrisqueta, Maria Jose Terol, Raquel de Campo, Pablo Mozas, Armando Lopez-Guillermo, Antonio Salar, Carlos Montalban
Summary: The aim of this study was to analyze compliance with the 2014 GELTAMO SMZL Guidelines and evaluate the outcome of splenic marginal zone lymphoma (SMZL) patients. A prospective multicenter study was conducted on 181 SMZL patients diagnosed between 2014 and 2020. The study found that 57% of patients followed the Guidelines, and the overall response rate was higher in the rituximab chemotherapy and rituximab arms compared to the splenectomy arm. The 5-year overall survival rate was 77% and the 5-year lymphoma-specific survival rate was 93%.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Zhen Yang, Lianshuang Liu, Kaiming Leng, Guangjun Shi
Summary: This study aimed to investigate the incidence, characteristics, treatment, and survival of splenic marginal zone lymphoma (SMZL). A total of 2790 SMZL patients were analyzed using the SEER-18 database. The study found a decreasing use of splenectomy but a relatively stable survival in SMZL patients. The study highlights the need for a better understanding of the role of splenectomy and its associated outcomes.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Christian Menzer, Adriana Rendon, Jessica C. Hassel
Summary: In patients with localized indolent cutaneous B-cell lymphoma (CBCL), intralesional rituximab (ILR) injections have shown similar efficacy to intravenous rituximab (IVR) infusions, making ILR a potential alternative for localized CBCL treatment. The majority of patients respond well to ILR, but relapse may occur in some cases.
Review
Oncology
Juan Pablo Alderuccio, Izidore S. Lossos
Summary: NOTCH signaling, particularly NOTCH2, plays a critical role in the pathogenesis of splenic marginal zone lymphoma (SMZL). Frequent mutations of NOTCH2 in SMZL underscore its importance in the disease. While NOTCH signaling presents an appealing target for drug discovery in SMZL, previous efforts have not shown meaningful clinical benefit or faced safety concerns.
LEUKEMIA & LYMPHOMA
(2022)
Article
Hematology
Rui Lyu, Tingyu Wang, Yi Wang, Wenjie Xiong, Huijun Wang, Yuting Yan, Qi Wang, Wei Liu, Gang An, Wenyang Huang, Weiwei Sui, Yan Xu, Dehui Zou, Jianxiang Wang, Lugui Qiu, Shuhua Yi
Summary: This study found that undetectable minimal residual disease (uMRD) in splenic marginal zone lymphoma (SMZL) patients is an independent prognostic factor, helping to predict patient survival.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Oncology
Xiaolu Yang, Ruonan Wang, Xiaochun Yuan, Shengyu Yao, Chungang Wang, Jinwei Cheng
Summary: This study found that ultra-low-dose radiotherapy is effective in the treatment of ocular adnexal lymphoma, providing excellent local disease control and long-term survival without significant toxicities.
RADIATION ONCOLOGY
(2022)